Author Affiliation: Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
A decade ago, practitioners who prescribed antihypertensive therapy,
and their patients, were transfixed by a passionate and sometimes unseemly
public debate over whether dihydropyridine calcium antagonists (not the verapamil
type) were safe.1 Aware that the available
scientific data were insufficient, contending parties, although agreeing on
little else, were all willing to submit their positions to the test of rigorous
clinical trials. The missing data now have been provided.2 Disappointingly,
while some concerns about calcium antagonists have been laid to rest, their
role in antihypertensive therapy remains controversial. Disputants who had
thrived on extrapolation from observational data now disagree about how to
interpret and apply the abundance of clinical trial data.
Alderman MH. The Return on INVEST. JAMA. 2003;290(21):2859-2861. doi:10.1001/jama.290.21.2859